BAXTER WILL NOT REPLACE PRESIDENT TOBIN FOLLOWING DEC. 23 RESIGNATION
This article was originally published in The Gray Sheet
Executive SummaryBAXTER WILL NOT REPLACE PRESIDENT TOBIN FOLLOWING DEC. 23 RESIGNATION; his duties as chief operating officer are being reallocated to the three remaining members of Baxter's Office of the Chief Executive: Chairman/CEO Vernon Loucks, Exec VP-Hospital Business Lester Knight, and Exec VP-Global Business Tony White. James Tobin, 49, resigned as president, chief operating officer and board member "effective immediately."
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.